Literature DB >> 22543594

Ritonavir and epidural triamcinolone as a cause of iatrogenic Cushing's syndrome.

Nicole E Albert1, Saifullah Kazi, Jerome Santoro, Rebecca Dougherty.   

Abstract

Ritonavir is a protease inhibitor (PI) frequently prescribed with highly active antiretroviral therapy. It functions to boost the effectiveness of other PIs as a result of blocking their breakdown by the cytochrome P450 (3A4) pathway. Through this same mechanism, ritonavir has been shown to cause iatrogenic Cushing's syndrome (ICS) in patients using inhaled fluticasone. In addition, a small number of recent cases suggest that ritonavir may also cause this disorder by prolonging the duration of injected corticosteroids, such as triamcinolone. This case report presents a human immunodeficiency virus (HIV) patient taking ritonavir with ICS and secondary adrenal insufficiency, presumably due to systemic absorption and decreased metabolism of an epidural triamcinolone injection. To the authors knowledge, there have only been 4 previously reported cases describing ritonavir-potentiating ICS after receiving a corticosteroid epidural. This provides further proof that caution should be taken with nonparenteral use of triamcinolone in HIV patients on PIs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543594     DOI: 10.1097/MAJ.0b013e31824ceb2b

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  10 in total

1.  Injecting epidural and intra-articular triamcinolone in HIV-positive patients on ritonavir: beware of iatrogenic Cushing's syndrome.

Authors:  M Maviki; P Cowley; H Marmery
Journal:  Skeletal Radiol       Date:  2012-11-15       Impact factor: 2.199

2.  Chronic Corticosterone Treatment During Adolescence Has Significant Effects on Metabolism and Skeletal Development in Male C57BL6/N Mice.

Authors:  Scott A Kinlein; Ziasmin Shahanoor; Russell D Romeo; Ilia N Karatsoreos
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

3.  High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy.

Authors:  Emily P Hyle; Brian R Wood; Elke S Backman; Farzad Noubary; Janice Hwang; Zhigang Lu; Elena Losina; Rochelle P Walensky; Rajesh T Gandhi
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

Review 4.  Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management.

Authors:  P Saberi; T Phengrasamy; D P Nguyen
Journal:  HIV Med       Date:  2013-04-16       Impact factor: 3.180

5.  Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature.

Authors:  C Schwarze-Zander; D Klingmüller; J Klümper; C P Strassburg; J K Rockstroh
Journal:  Infection       Date:  2013-07-20       Impact factor: 3.553

Review 6.  Iatrogenic cushing syndrome secondary to ritonavir-epidural triamcinolone interaction: an illustrative case and review.

Authors:  Sapna Sadarangani; Melody L Berg; William Mauck; Stacey Rizza
Journal:  Interdiscip Perspect Infect Dis       Date:  2014-05-07

Review 7.  Pharmacokinetic Drug-Drug Interactions Between Immunosuppressant and Anti-Infective Agents: Antimetabolites and Corticosteroids.

Authors:  Edward T Van Matre; Gowri Satyanarayana; Robert L Page 2nd; Marilyn E Levi; JoAnn Lindenfeld; Scott W Mueller
Journal:  Ann Transplant       Date:  2018-01-23       Impact factor: 1.530

Review 8.  Computational methods directed towards drug repurposing for COVID-19: advantages and limitations.

Authors:  Prem Prakash Sharma; Meenakshi Bansal; Aaftaab Sethi; Lindomar Pena; Vijay Kumar Goel; Maria Grishina; Shubhra Chaturvedi; Dhruv Kumar; Brijesh Rathi
Journal:  RSC Adv       Date:  2021-11-10       Impact factor: 4.036

9.  Hypothalamic-pituitary-adrenal axis suppression by inhaled or nasal corticosteroids in HIV-infected patients.

Authors:  Femke Besemer; Cornelis Kramers; Kees Brinkman; Ad R M M Hermus; Antonius E van Herwaarden; David M Burger
Journal:  Int J Clin Pharm       Date:  2020-03-05

Review 10.  What we have to know about corticosteroids use during Sars-Cov-2 infection.

Authors:  F Ferraù; F Ceccato; S Cannavò; C Scaroni
Journal:  J Endocrinol Invest       Date:  2020-08-28       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.